Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D J Kerr

Showing results (81-90 of 221) with videos related to

Pageof 23
Sort By:
British Journal of Cancer|August 28, 2003
Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracilD H Palmer, A E Milner, D J Kerr, et al.
British Journal of Cancer|June 1, 1992
A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastasesJ H Anderson, D J Kerr, T G Cooke, et al.
Journal of the Royal Naval Medical Service|March 1, 2000
EMIS: the story so farC J McArthur, J B McKeating, M R Groom, et al.
Biochemical Pharmacology|June 16, 1995
Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipineD R Ferry, P J Malkhandi, M A Russell, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1986
The effect of 5-fluorouracil on rat adrenal functionD J Kerr, A D Burt, G H Beastall, et al.
Biochemical Pharmacology|August 15, 1986
Comparative intracellular uptake of adriamycin and 4'-deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survivalD J Kerr, A M Kerr, R I Freshney, et al.
Cancer|April 20, 2001
Neural network and regression predictions of 5-year survival after colon carcinoma treatmentP B Snow, D J Kerr, J M Brandt, et al.
Cancer Drug Delivery|January 1, 1987
In vitro chemosensitivity testing using the multicellular tumor spheroid modelD J Kerr, T E Wheldon, A M Kerr, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Could interspecies differences in the protein binding of flavone acetic acid contribute to the failure to predict lack of efficacy in patients?J Cassidy, D J Kerr, A Setanoians, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Variability in the pharmacokinetics of epirubicin: a population analysisJ R Wade, A W Kelman, D J Kerr, et al.
Pageof 23

Showing results (81-90 of 221) with videos related to

Sort By:
Pageof 23
British Journal of Cancer|August 28, 2003
Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracilD H Palmer, A E Milner, D J Kerr, et al.
British Journal of Cancer|June 1, 1992
A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastasesJ H Anderson, D J Kerr, T G Cooke, et al.
Journal of the Royal Naval Medical Service|March 1, 2000
EMIS: the story so farC J McArthur, J B McKeating, M R Groom, et al.
Biochemical Pharmacology|June 16, 1995
Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipineD R Ferry, P J Malkhandi, M A Russell, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1986
The effect of 5-fluorouracil on rat adrenal functionD J Kerr, A D Burt, G H Beastall, et al.
Biochemical Pharmacology|August 15, 1986
Comparative intracellular uptake of adriamycin and 4'-deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survivalD J Kerr, A M Kerr, R I Freshney, et al.
Cancer|April 20, 2001
Neural network and regression predictions of 5-year survival after colon carcinoma treatmentP B Snow, D J Kerr, J M Brandt, et al.
Cancer Drug Delivery|January 1, 1987
In vitro chemosensitivity testing using the multicellular tumor spheroid modelD J Kerr, T E Wheldon, A M Kerr, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Could interspecies differences in the protein binding of flavone acetic acid contribute to the failure to predict lack of efficacy in patients?J Cassidy, D J Kerr, A Setanoians, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Variability in the pharmacokinetics of epirubicin: a population analysisJ R Wade, A W Kelman, D J Kerr, et al.
Pageof 23